This HTML5 document contains 107 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/national-drug-code-directory/
n29http://linked.opendata.cz/resource/AHFS/
n14http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/mesh/concept/
n7http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/chemspider/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/chebi/
n13http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n28http://www.rxlist.com/cgi/generic/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/pharmgkb/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00897/identifier/drugbank/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00897
rdf:type
n3:Drug
n3:description
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
n3:dosage
n7:271B5A1C-363D-11E5-9242-09173F13E4C5 n7:271B5A1D-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2883820 # Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines] Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2570451 # Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15037809 # Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17287588 # Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek] Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2773144
n3:group
approved
n3:halfLife
1.5-5.5 hours
n3:indication
For the short-term treatment of insomnia.
n3:manufacturer
n14:271B5A0D-363D-11E5-9242-09173F13E4C5 n14:271B5A0E-363D-11E5-9242-09173F13E4C5 n14:271B5A0F-363D-11E5-9242-09173F13E4C5 n14:271B5A10-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00897 n30:DB00897
dcterms:title
Triazolam
adms:identifier
n10:5355 n11:DB00897 n15:9674 n16:0054-4858-51 n17:PA451753 n18:D00387 n19:5556 n20:46509147 n21:Triazolam
n3:mechanismOfAction
Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA<sub>A</sub>) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
n3:packager
n14:271B5A0B-363D-11E5-9242-09173F13E4C5 n14:271B5A0C-363D-11E5-9242-09173F13E4C5 n14:271B5A0A-363D-11E5-9242-09173F13E4C5 n14:271B5A08-363D-11E5-9242-09173F13E4C5 n14:271B5A09-363D-11E5-9242-09173F13E4C5 n14:271B5A06-363D-11E5-9242-09173F13E4C5 n14:271B5A07-363D-11E5-9242-09173F13E4C5 n14:271B5A04-363D-11E5-9242-09173F13E4C5 n14:271B5A05-363D-11E5-9242-09173F13E4C5 n14:271B5A02-363D-11E5-9242-09173F13E4C5 n14:271B5A03-363D-11E5-9242-09173F13E4C5 n14:271B5A00-363D-11E5-9242-09173F13E4C5 n14:271B5A01-363D-11E5-9242-09173F13E4C5 n14:271B59FE-363D-11E5-9242-09173F13E4C5 n14:271B59FF-363D-11E5-9242-09173F13E4C5 n14:271B59FC-363D-11E5-9242-09173F13E4C5 n14:271B59FD-363D-11E5-9242-09173F13E4C5 n14:271B59FA-363D-11E5-9242-09173F13E4C5 n14:271B59FB-363D-11E5-9242-09173F13E4C5 n14:271B59F8-363D-11E5-9242-09173F13E4C5 n14:271B59F9-363D-11E5-9242-09173F13E4C5 n14:271B59F6-363D-11E5-9242-09173F13E4C5 n14:271B59F7-363D-11E5-9242-09173F13E4C5 n14:271B59F4-363D-11E5-9242-09173F13E4C5 n14:271B59F5-363D-11E5-9242-09173F13E4C5 n14:271B59F3-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Triazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion.
n3:synonym
Triazolam Triazolamum Halcion
n3:toxicity
Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.
n24:hasAHFSCode
n29:28-24-08
n5:hasConcept
n6:M0021910
foaf:page
n23:hal1192.shtml n27:triazolam.html n28:triazolam.htm
n3:IUPAC-Name
n4:271B5A22-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5A28-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5A27-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5A24-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5A25-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5A26-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5A20-363D-11E5-9242-09173F13E4C5 n4:271B5A38-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5A1E-363D-11E5-9242-09173F13E4C5 n4:271B5A21-363D-11E5-9242-09173F13E4C5 n4:271B5A3A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5A1F-363D-11E5-9242-09173F13E4C5 n4:271B5A3B-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:N05CD05
n3:H-Bond-Acceptor-Count
n4:271B5A2E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5A2F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5A29-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5A2A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5A2C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5A2B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5A2D-363D-11E5-9242-09173F13E4C5
n3:absorption
Bioavailability is 44% (oral) and 53% (sublingual).
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
28911-01-5
n3:category
n3:containedIn
n8:271B5A1A-363D-11E5-9242-09173F13E4C5 n8:271B5A1B-363D-11E5-9242-09173F13E4C5 n8:271B5A18-363D-11E5-9242-09173F13E4C5 n8:271B5A19-363D-11E5-9242-09173F13E4C5 n8:271B5A16-363D-11E5-9242-09173F13E4C5 n8:271B5A17-363D-11E5-9242-09173F13E4C5 n8:271B5A14-363D-11E5-9242-09173F13E4C5 n8:271B5A15-363D-11E5-9242-09173F13E4C5 n8:271B5A12-363D-11E5-9242-09173F13E4C5 n8:271B5A13-363D-11E5-9242-09173F13E4C5 n8:271B5A11-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5A34-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5A36-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5A37-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5A39-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5A33-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5A32-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5A35-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5A23-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5A30-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5A31-363D-11E5-9242-09173F13E4C5